Skip to main content

Table 3 Virological and immunological outcomes in participants taking DTG-based ART (n is variable depending on availability of data)

From: Efficacy, safety, and tolerability of dolutegravir-based ART regimen in Durban, South Africa: a cohort study

Variable

Baseline

Frequency

(Proportion %)

After DTG-based ART

Frequency

(Proportion %)

T-test

(p)

VL (copies/ml) (n = 408)

   

< 50

50 − 999

≥ 1000

Mean

376 (92.2)

27 (6.6)

5 (1.2)

337.41 ± 3365.26

375 (91.9)

29 (7.1)

43 (1.0)

88.54 ± 325.68

0.138

CD4 (cells/mm3)(n = 344)

< 200

200 − 350

351 − 500

> 500

Mean

19 (5.5)

39 (11.3)

73 (21.2)

213 (61.9)

599.49 ± 261.36

6 (1.7)

38 (11.1)

47 (13.7)

252 (73.3)

681.67 ± 290.40

< 0.001